Dr. Marie M. Budev, DO
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- New York College of Osteo Medicine of New York Institute of Technology (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 95
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: New York College of Osteo Medicine of New York Institute of Technology
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
OH license 34006831
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cleveland Clinic Cleveland, OH
- Akron General Medical Center Akron, OH
Medical groups
- Cleveland Clinic (7,090 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 95
- Services billed
- 521
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 281 | 51 |
| Established patient office or other outpatient visit, 40-54 minutes | 116 | 45 |
| Critical care, first 30-74 minutes | 105 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Cleveland, OH | 230 |
| Azithromycin Other prescribers in Cleveland, OH | 167 |
| Prednisone Other prescribers in Cleveland, OH | 154 |
| Atorvastatin Calcium Other prescribers in Cleveland, OH | 140 |
| Tacrolimus Other prescribers in Cleveland, OH | 136 |
| Pantoprazole Sodium Other prescribers in Cleveland, OH | 124 |
| Metoprolol Tartrate Other prescribers in Cleveland, OH | 98 |
| Valganciclovir Hcl | 57 |
| Gabapentin Other prescribers in Cleveland, OH | 53 |
| Acyclovir Other prescribers in Cleveland, OH | 50 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 44 payments worth $58,036 in total to this clinician.
| United Therapeutics Corporation | $32,938 |
|---|---|
| Sanofi-aventis U.S. LLC | $12,750 |
| Sanofi US Services Inc. | $8,102 |
| Kamada LTD. | $2,144 |
| Transmedics, Inc. | $2,021 |
| Zambon USA LTD. | $46.36 |
| La Jolla Pharmaceutical Company | $34.38 |
| Consulting Fee | $39,965 |
|---|---|
| Travel and Lodging | $14,964 |
| Compensation for services other than consulting (speaking, faculty) | $2,040 |
| Food and Beverage | $1,066 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sanofi-aventis U.S. LLC Jul 11, 2025 | Consulting Fee REZUROCK · Oncology | $12,750 |
| Sanofi US Services Inc. Jul 11, 2025 | Travel and Lodging REZUROCK · Oncology · travel to Paris, France · in-kind | $6,426 |
| United Therapeutics Corporation Nov 26, 2025 | Consulting Fee | $5,390 |
| United Therapeutics Corporation Jun 11, 2025 | Consulting Fee STEEN SOLUTION · Lung Transplant | $4,900 |
| United Therapeutics Corporation Mar 26, 2025 | Consulting Fee | $4,165 |
| United Therapeutics Corporation Dec 24, 2025 | Consulting Fee | $3,450 |
| United Therapeutics Corporation Sep 10, 2025 | Consulting Fee STEEN SOLUTION · Lung Transplant | $2,940 |
| United Therapeutics Corporation Sep 10, 2025 | Consulting Fee STEEN SOLUTION · Lung Transplant | $2,940 |
| Kamada LTD. Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) CYTOGAM · Infections and Infectious Diseases | $2,040 |
| United Therapeutics Corporation Mar 26, 2025 | Consulting Fee | $1,715 |
All 26 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| United Therapeutics Corporation Dec 24, 2025 | Consulting Fee | $3,450 |
| United Therapeutics Corporation Nov 26, 2025 | Consulting Fee | $5,390 |
| United Therapeutics Corporation Nov 26, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $757 |
| United Therapeutics Corporation Nov 26, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $308 |
| United Therapeutics Corporation Nov 26, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $150 |
| Transmedics, Inc. Nov 3, 2025 | Travel and Lodging Organ Care System · Device · travel to BOSTON, MA | $1,044 |
| Transmedics, Inc. Oct 29, 2025 | Travel and Lodging Organ Care System · Device · travel to BOSTON, MA | $827 |
| United Therapeutics Corporation Sep 10, 2025 | Consulting Fee STEEN SOLUTION · Lung Transplant | $2,940 |
| United Therapeutics Corporation Sep 10, 2025 | Consulting Fee STEEN SOLUTION · Lung Transplant | $2,940 |
| United Therapeutics Corporation Sep 10, 2025 | Travel and Lodging STEEN SOLUTION · Lung Transplant · travel to Nashville, TN · in-kind | $1,611 |
| United Therapeutics Corporation Sep 10, 2025 | Travel and Lodging STEEN SOLUTION · Lung Transplant · travel to Nashville, TN · in-kind | $207 |
| Sanofi-aventis U.S. LLC Jul 11, 2025 | Consulting Fee REZUROCK · Oncology | $12,750 |
| Sanofi US Services Inc. Jul 11, 2025 | Travel and Lodging REZUROCK · Oncology · travel to Paris, France · in-kind | $6,426 |
| Sanofi US Services Inc. Jul 11, 2025 | Travel and Lodging REZUROCK · Oncology · travel to Paris, France · in-kind | $834 |
| Sanofi US Services Inc. Jul 11, 2025 | Travel and Lodging REZUROCK · Oncology · travel to Paris, France · in-kind | $407 |
| Sanofi US Services Inc. Jul 11, 2025 | Travel and Lodging REZUROCK · Oncology · travel to Paris, France | $368 |
| United Therapeutics Corporation Jun 11, 2025 | Consulting Fee STEEN SOLUTION · Lung Transplant | $4,900 |
| United Therapeutics Corporation Jun 11, 2025 | Travel and Lodging STEEN SOLUTION · Lung Transplant · travel to Washington, DC · in-kind | $946 |
| United Therapeutics Corporation Jun 11, 2025 | Travel and Lodging STEEN SOLUTION · Lung Transplant · travel to Washington, DC · in-kind | $193 |
| Kamada LTD. Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) CYTOGAM · Infections and Infectious Diseases | $2,040 |
| United Therapeutics Corporation Mar 26, 2025 | Consulting Fee | $4,165 |
| United Therapeutics Corporation Mar 26, 2025 | Consulting Fee | $1,715 |
| United Therapeutics Corporation Mar 26, 2025 | Travel and Lodging travel to Scottsdale, AZ · in-kind | $478 |
| United Therapeutics Corporation Mar 26, 2025 | Travel and Lodging travel to Scottsdale, AZ · in-kind | $260 |
| United Therapeutics Corporation Feb 26, 2025 | Consulting Fee STEEN SOLUTION · Lung Transplant | $1,715 |
| Transmedics, Inc. Jan 9, 2025 | Travel and Lodging Organ Care System · Device · travel to Boston, MA | $150 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $89,053 in research payments for these studies, mostly to the institutions running them.
- A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
Sanofi US Services Inc. · Recruiting · NCT06082037 - A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110)
Incyte Corporation - A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.